Investigational Drug Information for Ibudilast
✉ Email this page to a colleague
What is the development status for investigational drug Ibudilast?
Ibudilast is an investigational drug.
There have been 22 clinical trials for Ibudilast.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Alcoholism, Alcohol Drinking, and Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).
There are seven hundred and ninety-two US patents protecting this investigational drug and zero international patents.
Summary for Ibudilast
| US Patents | 792 |
| International Patents | 7,904 |
| US Patent Applications | 2,945 |
| WIPO Patent Applications | 1,242 |
| Japanese Patent Applications | 860 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 65 |
Recent Clinical Trials for Ibudilast
| Title | Sponsor | Phase |
|---|---|---|
| Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study | University of Pennsylvania | Early Phase 1 |
| A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder | University of Pennsylvania | Phase 2 |
| Canadian Adaptive Platform Trial for Long COVID | University Health Network, Toronto | Phase 2/Phase 3 |
Clinical Trial Summary for Ibudilast
Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast
US Patents for Ibudilast
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibudilast | ⤷ Subscribe | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Melanocortin-1 receptor-specific cyclic hexapeptides | Palatin Technologies, Inc. (Cranbury, NJ) | ⤷ Subscribe |
| Ibudilast | ⤷ Subscribe | Pyrazolopyridines and pyrazolopyrimidines | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibudilast
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibudilast | Canada | CA2961033 | 2034-09-11 | ⤷ Subscribe |
| Ibudilast | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Subscribe |
| Ibudilast | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Subscribe |
| Ibudilast | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | ⤷ Subscribe |
| Ibudilast | Australia | AU2012222348 | 2031-03-01 | ⤷ Subscribe |
| Ibudilast | Australia | AU2012222351 | 2031-03-01 | ⤷ Subscribe |
| Ibudilast | Australia | AU2013224959 | 2031-03-01 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
